Free Trial
NASDAQ:ONC

Beigene 2/27/2025 Earnings Report

Beigene logo
$240.41 +2.10 (+0.88%)
As of 05/28/2025 04:00 PM Eastern

Beigene EPS Results

Actual EPS
-$1.43
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.55
One Year Ago EPS
N/A

Beigene Revenue Results

Actual Revenue
$1.13 billion
Expected Revenue
$1.09 billion
Beat/Miss
Beat by +$40.85 million
YoY Revenue Growth
N/A

Beigene Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Beigene Earnings Headlines

BeOne Launches Following Move to Switzerland
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Beigene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beigene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beigene and other key companies, straight to your email.

About Beigene

Beigene (NASDAQ:ONC) Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

View Beigene Profile

More Earnings Resources from MarketBeat